Free Trial

HUTCHMED (HCM) Competitors

HUTCHMED logo
$17.66 -0.12 (-0.65%)
As of 01:40 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HCM vs. MRNA, RDY, QGEN, VTRS, ASND, VRNA, BBIO, BPMC, ROIV, and LEGN

Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Moderna (MRNA), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.

HUTCHMED vs. Its Competitors

Moderna (NASDAQ:MRNA) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

HUTCHMED has a net margin of 0.00% compared to Moderna's net margin of -105.67%. HUTCHMED's return on equity of 0.00% beat Moderna's return on equity.

Company Net Margins Return on Equity Return on Assets
Moderna-105.67% -28.69% -21.94%
HUTCHMED N/A N/A N/A

In the previous week, Moderna had 9 more articles in the media than HUTCHMED. MarketBeat recorded 12 mentions for Moderna and 3 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.16 beat Moderna's score of 0.16 indicating that HUTCHMED is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Moderna
6 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
HUTCHMED
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

HUTCHMED has lower revenue, but higher earnings than Moderna.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moderna$3.24B4.07-$3.56B-$8.73-3.90
HUTCHMED$630.20M4.89$37.73MN/AN/A

75.3% of Moderna shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 11.0% of Moderna shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Moderna has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Moderna currently has a consensus price target of $46.11, suggesting a potential upside of 35.46%. HUTCHMED has a consensus price target of $23.50, suggesting a potential upside of 33.03%. Given Moderna's higher possible upside, research analysts plainly believe Moderna is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moderna
4 Sell rating(s)
17 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.04
HUTCHMED
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Moderna beats HUTCHMED on 8 of the 15 factors compared between the two stocks.

Get HUTCHMED News Delivered to You Automatically

Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HCM vs. The Competition

MetricHUTCHMEDMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.08B$3.03B$5.70B$9.52B
Dividend YieldN/A2.40%4.60%3.99%
P/E RatioN/A21.0128.0020.01
Price / Sales4.89335.54457.41102.39
Price / Cash61.1743.2336.5558.97
Price / Book3.998.248.595.87
Net Income$37.73M-$55.19M$3.24B$258.50M
7 Day Performance0.43%5.35%3.71%1.95%
1 Month Performance14.11%17.07%10.26%12.31%
1 Year Performance-1.92%4.53%34.07%19.02%

HUTCHMED Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HCM
HUTCHMED
2.8149 of 5 stars
$17.67
-0.6%
$23.50
+33.0%
-5.1%$3.08B$630.20M0.001,811Positive News
Analyst Forecast
MRNA
Moderna
4.2415 of 5 stars
$30.97
-0.9%
$46.61
+50.5%
-71.2%$12.09B$3.24B-3.555,800Upcoming Earnings
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.7236 of 5 stars
$14.57
+0.6%
$16.95
+16.4%
-8.1%$12.09B$3.81B21.9427,811Earnings Report
QGEN
QIAGEN
3.7063 of 5 stars
$48.06
-0.6%
$49.40
+2.8%
+25.6%$10.75B$1.98B120.495,765Positive News
Analyst Revision
VTRS
Viatris
2.3592 of 5 stars
$8.90
+0.2%
$10.40
+16.9%
-20.1%$10.42B$14.74B-2.8132,000
ASND
Ascendis Pharma A/S
3.4985 of 5 stars
$168.02
-1.1%
$223.07
+32.8%
+25.6%$10.39B$393.54M-26.751,017Analyst Revision
VRNA
Verona Pharma PLC American Depositary Share
2.6872 of 5 stars
$104.90
flat
$109.00
+3.9%
+398.3%$8.93B$42.28M-52.4530Positive News
BBIO
BridgeBio Pharma
4.6151 of 5 stars
$45.90
-1.3%
$61.50
+34.0%
+73.2%$8.83B$221.90M-13.00400
BPMC
Blueprint Medicines
0.972 of 5 stars
$129.46
flat
$128.25
-0.9%
N/A$8.36B$562.12M-52.41640Upcoming Earnings
ROIV
Roivant Sciences
2.6491 of 5 stars
$11.48
+0.3%
$16.50
+43.7%
+5.9%$7.78B$29.05M-45.92860News Coverage
Positive News
Insider Trade
LEGN
Legend Biotech
3.6854 of 5 stars
$42.23
+1.5%
$73.33
+73.7%
-25.9%$7.64B$627.24M-71.582,609Positive News

Related Companies and Tools


This page (NASDAQ:HCM) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners